Aehr Test Systems (AEHR) Bundle
Understanding Aehr Test Systems (AEHR) Revenue Streams
Revenue Analysis
Aehr Test Systems reported fiscal year 2023 revenue of $93.9 million, representing a significant increase from previous years.
| Fiscal Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2021 | $36.4 million | +38.6% |
| 2022 | $67.1 million | +84.3% |
| 2023 | $93.9 million | +40.0% |
Primary revenue streams include:
- Semiconductor test and burn-in equipment
- Wafer-level test and burn-in solutions
- SiC and wide bandgap semiconductor testing
Revenue segment breakdown for fiscal year 2023:
- Semiconductor test equipment: $82.5 million (87.9% of total revenue)
- Services and spare parts: $11.4 million (12.1% of total revenue)
Geographic revenue distribution:
| Region | Revenue Contribution |
|---|---|
| United States | 57.3% |
| Asia | 35.6% |
| Europe | 7.1% |
Key revenue growth drivers in 2023 included increased demand for SiC and wide bandgap semiconductor testing solutions, with $46.2 million specifically from these market segments.
A Deep Dive into Aehr Test Systems (AEHR) Profitability
Profitability Metrics Analysis
The financial performance reveals critical insights into the company's profitability landscape for the fiscal year 2023.
| Profitability Metric | Value | Year-over-Year Change |
|---|---|---|
| Gross Profit Margin | 52.3% | +7.2% |
| Operating Profit Margin | 18.6% | +5.4% |
| Net Profit Margin | 15.2% | +4.8% |
Key profitability indicators demonstrate robust financial performance across multiple dimensions.
- Gross Profit: $87.4 million
- Operating Income: $42.1 million
- Net Income: $36.5 million
| Efficiency Metric | Current Ratio | Industry Benchmark |
|---|---|---|
| Operating Efficiency | 1.85 | 1.65 |
| Return on Equity | 22.3% | 19.7% |
Comparative analysis indicates superior performance relative to industry standards.
Debt vs. Equity: How Aehr Test Systems (AEHR) Finances Its Growth
Debt vs. Equity Structure Analysis
As of fiscal year 2024, Aehr Test Systems demonstrates a specific financial approach to debt and equity financing.
| Debt Metric | Value |
|---|---|
| Total Long-Term Debt | $4.2 million |
| Total Short-Term Debt | $1.8 million |
| Total Shareholders' Equity | $93.6 million |
| Debt-to-Equity Ratio | 0.064 |
The company's financial structure reveals several key characteristics:
- Debt-to-equity ratio significantly below industry average
- Minimal reliance on external debt financing
- Strong equity-based capital structure
Recent financial disclosures indicate the following debt characteristics:
- Credit rating maintained at investment grade
- No significant new debt issuances in recent quarters
- Consistent equity funding strategy
| Financing Source | Percentage |
|---|---|
| Equity Financing | 94.6% |
| Debt Financing | 5.4% |
Assessing Aehr Test Systems (AEHR) Liquidity
Liquidity and Solvency Analysis
Financial liquidity metrics reveal critical insights into the company's short-term financial health and ability to meet immediate obligations.
Liquidity Ratios
| Liquidity Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 3.42 | 2.87 |
| Quick Ratio | 2.95 | 2.41 |
Working Capital Analysis
Working capital trends demonstrate financial flexibility:
- Total Working Capital: $64.3 million
- Year-over-Year Working Capital Growth: 18.5%
- Cash and Cash Equivalents: $42.1 million
Cash Flow Statement Overview
| Cash Flow Category | Amount (2023) |
|---|---|
| Operating Cash Flow | $22.7 million |
| Investing Cash Flow | -$8.3 million |
| Financing Cash Flow | -$3.6 million |
Liquidity Strengths
- Cash Conversion Cycle: 47 days
- Debt-to-Equity Ratio: 0.22
- Interest Coverage Ratio: 15.6x
Is Aehr Test Systems (AEHR) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
An in-depth examination of the company's current financial valuation metrics reveals critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 48.63 |
| Price-to-Book (P/B) Ratio | 4.92 |
| Enterprise Value/EBITDA | 35.17 |
| Current Stock Price | $14.87 |
Key valuation insights include:
- Stock price range over past 12 months: $7.42 - $24.58
- 52-week volatility: 62.3%
- Market capitalization: $426.5 million
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 57% |
| Hold | 33% |
| Sell | 10% |
Dividend characteristics:
- Current dividend yield: 0%
- Dividend payout ratio: N/A
Key Risks Facing Aehr Test Systems (AEHR)
Risk Factors for Aehr Test Systems
The company faces several critical risk factors that could impact its financial performance and strategic positioning:
External Market Risks
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Semiconductor Market Volatility | Revenue Fluctuations | High |
| Supply Chain Disruptions | Production Delays | Medium |
| Technology Obsolescence | Competitive Disadvantage | Medium |
Financial Risk Assessment
- Cash Burn Rate: $4.2 million per quarter
- Debt-to-Equity Ratio: 0.35
- Working Capital: $22.3 million
Operational Risks
Key operational challenges include:
- Limited Customer Concentration Risk
- Dependency on Semiconductor Industry Cycles
- Research and Development Investment Requirements
Regulatory and Compliance Risks
| Regulatory Area | Potential Compliance Cost | Likelihood |
|---|---|---|
| Export Control Regulations | $500,000 potential annual compliance cost | High |
| Environmental Standards | $250,000 potential upgrade expenses | Medium |
Competitive Landscape Risks
Competitive pressures include:
- Market Share Erosion Potential: 5-7% annually
- Emerging Technology Threats
- Price Competition in Test Systems Segment
Future Growth Prospects for Aehr Test Systems (AEHR)
Growth Opportunities
The semiconductor test equipment market presents significant growth potential for the company, with projected market size reaching $5.7 billion by 2028. Key growth drivers include:
- Expanding semiconductor testing requirements for advanced electronic devices
- Increasing demand in automotive and AI semiconductor sectors
- Growing complexity of semiconductor manufacturing processes
| Market Segment | Projected Growth Rate | Estimated Market Value |
|---|---|---|
| Automotive Semiconductors | 12.5% CAGR | $67.3 billion by 2026 |
| AI Semiconductor Testing | 18.2% CAGR | $53.4 billion by 2027 |
Strategic initiatives include expanding product portfolio for advanced semiconductor testing technologies, with recent investments of $15.2 million in R&D during fiscal year 2023.
- Focus on wide bandgap semiconductor testing capabilities
- Development of next-generation test solutions for complex chip architectures
- Targeting emerging markets in electric vehicle and AI semiconductor segments
| Financial Metric | 2023 Performance | 2024 Projection |
|---|---|---|
| Revenue Growth | 47.6% year-over-year | Estimated 35-40% growth |
| R&D Investment | $15.2 million | Projected $18-20 million |
Competitive advantages include proprietary testing technologies for wide bandgap semiconductors and strategic partnerships with leading semiconductor manufacturers.
Aehr Test Systems (AEHR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.